Table 1.

Primary and sensitivity analyses.

Analysis	Endpoints	Study criteria	Assessment period
			∼24 weeks	∼52 weeks	Study end
Primary analysis Full publications	Change from baseline in number of headache days	All studies	✓	✓
		Prospective studies*	✓	✓
	Change from baseline in number of days of acute headache pain medication intake	All studies	✓	✓
		Prospective studies*	N/A	N/A
	Rate of ≥50% reduction in migraine days	All studies	✓	N/A
		Prospective studies*	✓	N/A
	Change from baseline in total HIT-6 score	All studies	✓	✓
		Prospective studies*	N/A	N/A
	Change from baseline in MSQ score	All studies	✓	✓
		Prospective studies*
	MIDAS score	All studies	✓	N/A
		Prospective studies*	✓	N/A
Sensitivity analysis 1Full publications	Change from baseline in number of headache days	All studies			✓
		Prospective studies*			✓
	Change from baseline in number of days of acute headache pain medication intake	All studies			✓
		Prospective studies*			✓
	Change from baseline in total HIT-6 score	All studies			✓
		Prospective studies*			✓
	Change from baseline in MSQ score	All studies			✓
		Prospective studies*
	MIDAS score	All studies			✓
		Prospective studies*			✓
Sensitivity analysis 2Full publications + congress abstracts/presentations	Change from baseline in number of headache days	All studies	(Same as primary analysis)	✓
Sensitivity analysis 3Full publications	Change from baseline in number of headache days	All studies: sponsored vs unsponsored	✓	–

*With durations of least 24 weeks; N/A: not applicable,